Alemtuzumab is a highly effective therapy for relapsing-remitting MS (RRMS) with secondary autoimmunity as a main adverse event. Here, we present a case of microscopic polyangiitis (MPA) in a patient with RRMS secondary to alemtuzumab therapy.
1

Discussion
MPA is a necrotizing small-vessel vasculitis with common focal necrotizing, pauci-immune glomerulonephritis, pulmonary capillaritis, and purpura. 1, 2 In our patient, diagnosis of MPA was confirmed by purpura-like exanthema in the context of leukocytoclastic vasculitis and the characteristic detection of MPO-ANCA in the absence of thrombocytopenia. The pathogenesis of MPA likely comprises an interplay between neutrophils, lymphocytes, endothelium, cytokine-mediated changes, the alternative pathway of the complement system, and MPO-ANCA. 2 For maintenance immunosuppression, rituximab, methotrexate, mycophenolate mofetil, or azathioprine is recommended. 1 In our case, an association between alemtuzumab treatment and MPA may be assumed, although a causal relationship cannot be confirmed. Alemtuzumab, a humanized monoclonal antibody against the surface glycoprotein CD52 temporarily depletes B and T cells and induces prolonged T-cell lymphopenia. 3 It is associated with secondary B cellmediated autoimmunity mostly affecting the thyroid, less frequently immune thrombocytopenia or glomerular nephropathies. 3 Uncommon complications such as antiglomerular basement membrane disease 4 or leukocytoclastic vasculitis 5 were also reported. These antibody-mediated autoimmune diseases may stem from an altered immune repertoire with early and predominant recovery of B cells. The occurrence of MPA in our patient fits well with the time frame in which B-cell reconstitution occurs following alemtuzumab. 3 The overshooting B-cell repopulation including potentially autoreactive B cells emerging in the relative absence of T-cell regulation may explain the resulting secondary autoimmunity in our case.
3 Since B-lymphocytes are essential in the pathogenesis of MPA 2 and RRMS, B-cell depletion would be a promising strategy to control B-cell hyperproliferation.
MPA should be considered in the differential diagnosis of purpura-like efflorescence after alemtuzumab therapy. Early identification and immediate treatment are vital to resolve symptoms, prevent pulmonary-renal damage, and minimize mortality.
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